Here is the design of a clinical trial:

Official Title: The Canadian Study of Arterial Inflammation in Patients With Diabetes and Recent Vascular Events: EvaluatioN of Colchicine Effectiveness (CADENCE)

Included conditions:
- Cardiovascular Diseases
- Atherosclerosis
- Inflammation
- Diabetes

Study Armgroups:
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Placebo: Sugar pill manufactured to mimic colchicine 0.6 mg capsule. Placebo to be taken once a day.', 'interventionNames': ['Drug: Placebo oral capsule']}
- {'label': 'Colchicine', 'type': 'EXPERIMENTAL', 'description': 'Colchicine: 0.6 mg colchicine capsule to be taken once a day.', 'interventionNames': ['Drug: Colchicine Oral Product']}

Interventions:
- {'type': 'DRUG', 'name': 'Colchicine Oral Product', 'description': 'Patients will be randomized to receive either placebo or colchicine', 'armGroupLabels': ['Colchicine']}
- {'type': 'DRUG', 'name': 'Placebo oral capsule', 'description': 'Patents will be randomized to receive either placebo or colchicine', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': '6 month change in FDG uptake TBR (Tissue to Blood Ratio) in the MDS (Maximum Disease Segment)', 'description': 'The primary endpoint will be the change over 6 months in the FDG uptake TBR (Tissue-to-blood ratio) as a marker of arterial plaque inflammation in the maximum disease segment (MDS)(the segment with the highest TBR at baseline) in any vasculature imaged whether it be left or right carotid or aorta.', 'timeFrame': '6 months'}

Please estimate the sample size based on the assumption: 
For a 10% reduction compared with placebo with a power of 80%, alpha 0.05, considering 10% withdrawal, and 2% of patients who complete baseline measures but do not start study drug.
Sample size
        There are no previously published studies evaluating FDG over time in patients with T2DM or pre-diabetes who have suffered recent CV events (our study population) on which to base a definitive sample size calculation. We evaluated the ascending aorta as a non-culprit region in patients from our prior study17 with diabetes and recent events where the aorta was in the field of view (n=6): TBRmax=3.38Â±0.60. In the culprit carotid arteries in patients with diabetes (n=12) TBRmax was 3.58Â±0.00.88.
        Based on the literature and feedback from experts, the minimal clinically important difference (MCID) in TBRmax reduction is 10%â15%. This is feasible since FDG differences between treatments in prior studies was also 10%â14%.20 21 Taking a conservative approach based on our TBRmax values in our patients with T2DM with recent events, for a 10% reduction compared with placebo with a power of 80%, alpha 0.05, we will need 50 patients per group. Considering 10% withdrawal, and 2% of patients who complete baseline measures but do not start study drug, 115 patients will be recruited (12/115 (10.4%) withdrawal and 3/115 (2.6%) not starting drug), both similar to the LoDoCo trial.36 Prior studies have included 21â34 patients/group.20 21 37 38 Thus, our sample size is expected to enable us to address our hypothesis.